Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?

Key Takeaways Investors responded with optimism following CVS Health's (CVS) second-quarter 2025 earnings release last week, buoyed by better-than-expected earnings and revenue growth, improved segment performance and an upward revision to full-year guidance, reflecting operational momentum in its Health Care Benefits and Pharmacy & Consumer Wellness segments. This, coupled with a strong year-to-date cash flow of $6.5 billion, confirms that CVS is on track with its long-term strategy, even amid industry-wid ...